Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/NeOnc Technologies Holdings, Inc./ 8-K/A

Current Report · Items 5.02 · 8-K/A

NeOnc Technologies Holdings, Inc.

NTHINASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 18, 2026, the Board appointed Nasim Shomali to serve as a member of the Audit Committee of the Board, effective immediately. Following Nasim Shomali’s appointment to the Audit Committee, such committee will be comprised of the following directors:…

Filed Aug 21, 2026Accepted Aug 21, 2026, 2:58 PM EDTCIK 1979414Accession 0001829126-26-009220
View company →Permanent SEC source ↗
Share

Company context

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.

Current securities

NTHINASDAQ · EQUITY · Current

Recent company filings

  1. Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureSep 21, 2026
  2. Regulation FD DisclosureSep 17, 2026
  3. 4 filingSep 15, 2026
  4. 4 filingSep 14, 2026
  5. Entry into a Material Definitive Agreement · Regulation FD DisclosureSep 10, 2026

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 18, 2026, the Board appointed Nasim Shomali to serve as a member of the Audit Committee of the Board, effective immediately. Following Nasim Shomali’s appointment to the Audit Committee, such committee will be comprised of the following directors: Bader Almonawer (Chair of the Audit Committee), Jim Delshad and Nasim Shomali.